Fecal microbiota transplantation is not a magical treatment, but better too early than too late.
作者信息
Shin Jongbeom
机构信息
Digestive Disease Center, Department of Internal Medicine, Inha University College of Medicine, Incheon, Korea.
出版信息
Korean J Intern Med. 2023 Jan;38(1):3-4. doi: 10.3904/kjim.2022.377. Epub 2022 Dec 28.
Abstract
摘要
相似文献
1
Fecal microbiota transplantation is not a magical treatment, but better too early than too late.粪便微生物群移植并非神奇疗法，但早做比晚做好。
Korean J Intern Med. 2023 Jan;38(1):3-4. doi: 10.3904/kjim.2022.377. Epub 2022 Dec 28.
2
The AGA's Fecal Microbiota Transplantation National Registry: An Important Step Toward Understanding Risks and Benefits of Microbiota Therapeutics.美国胃肠病学会的粪便微生物群移植国家登记处：迈向了解微生物群疗法风险与益处的重要一步。
Gastroenterology. 2017 Mar;152(4):681-684. doi: 10.1053/j.gastro.2017.01.028. Epub 2017 Jan 29.
3
Antimicrobial Resistance Gene Acquisition and Depletion Following Fecal Microbiota Transplantation for Recurrent Clostridium difficile Infection.粪菌移植治疗复发性艰难梭菌感染后抗菌药物耐药基因的获得和减少。
Clin Infect Dis. 2018 Jan 18;66(3):456-457. doi: 10.1093/cid/cix821.
4
Evaluating Donor Microbiome Before Fecal Microbiota Transplantation.粪便微生物群移植前评估供体微生物组。
Gastroenterology. 2022 Mar;162(3):993-994. doi: 10.1053/j.gastro.2021.07.003. Epub 2021 Jul 9.
5
Fecal microbiota transplantation in gastrointestinal disease: 2015 update and the road ahead.胃肠道疾病中的粪便微生物群移植：2015年更新及未来之路
Expert Rev Gastroenterol Hepatol. 2015;9(11):1379-91. doi: 10.1586/17474124.2015.1086267. Epub 2015 Sep 28.
6
The effect of fecal microbiota transplantation on stroke outcomes: A systematic review.粪便微生物群移植对脑卒中结局的影响：系统评价。
J Stroke Cerebrovasc Dis. 2022 Nov;31(11):106727. doi: 10.1016/j.jstrokecerebrovasdis.2022.106727. Epub 2022 Sep 23.
7
Bifidobacterium-Rich Fecal Donor May Be a Positive Predictor for Successful Fecal Microbiota Transplantation in Patients with Irritable Bowel Syndrome.富含双歧杆菌的粪便供体可能是肠易激综合征患者粪便微生物群移植成功的一个积极预测指标。
Digestion. 2017;96(1):29-38. doi: 10.1159/000471919. Epub 2017 Jun 21.
8
Fecal microbiota transplantation treatment of autoimmune-mediated type 1 diabetes: A systematic review.粪便微生物群移植治疗自身免疫介导的 1 型糖尿病：系统评价。
Front Cell Infect Microbiol. 2022 Dec 1;12:1075201. doi: 10.3389/fcimb.2022.1075201. eCollection 2022.
9
Current applications of fecal microbiota transplantation in intestinal disorders.粪便微生物群移植在肠道疾病中的应用现状。
Kaohsiung J Med Sci. 2019 Jun;35(6):327-331. doi: 10.1002/kjm2.12069. Epub 2019 Apr 24.
10
[Chinese experts consensus on standardized methodology and clinical application of fecal microbiota transplantation].[中国粪便微生物群移植标准化方法及临床应用专家共识]
Zhonghua Wei Chang Wai Ke Za Zhi. 2020 Jul 10;23(Z1):5-13. doi: 10.3760/cma.j.cn.441530-20200420-00231.
本文引用的文献
1
Gut microbiota differs between treatment outcomes early after fecal microbiota transplantation against recurrent infection.粪菌移植治疗复发性感染早期的治疗效果存在肠道菌群差异。
Gut Microbes. 2022 Jan-Dec;14(1):2084306. doi: 10.1080/19490976.2022.2084306.
2
Recognition and attitudes of Korean physicians toward fecal microbiota transplantation: a survey study.韩国医生对粪便微生物群移植的认知和态度：一项调查研究。
Korean J Intern Med. 2023 Jan;38(1):48-55. doi: 10.3904/kjim.2022.206. Epub 2022 Nov 10.
3
Clinical Practice Guidelines for Fecal Microbiota Transplantation in Korea.韩国粪便微生物群移植临床实践指南。
J Neurogastroenterol Motil. 2022 Jan 30;28(1):28-42. doi: 10.5056/jnm21221.
4
The use of Faecal Microbiota Transplantation (FMT) in Europe: A Europe-wide survey.欧洲粪便微生物群移植（FMT）的应用：一项全欧洲范围的调查。
Lancet Reg Health Eur. 2021 Jul 19;9:100181. doi: 10.1016/j.lanepe.2021.100181. eCollection 2021 Oct.
5
Fecal microbiota transplantation in human metabolic diseases: From a murky past to a bright future?人类代谢性疾病中的粪便微生物群移植：从模糊的过去走向光明的未来？
Cell Metab. 2021 Jun 1;33(6):1098-1110. doi: 10.1016/j.cmet.2021.05.005.
6
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.SER-109，一种用于减少艰难梭菌感染后复发的研究性微生物组药物：来自 2 期试验的经验教训。
Clin Infect Dis. 2021 Jun 15;72(12):2132-2140. doi: 10.1093/cid/ciaa387.
7
Drug-Resistant Bacteremia Transmitted by Fecal Microbiota Transplant.耐药菌血症通过粪便微生物群移植传播。
N Engl J Med. 2019 Nov 21;381(21):2043-2050. doi: 10.1056/NEJMoa1910437. Epub 2019 Oct 30.
8
Fecal Microbiota Transplantation Is Superior to Fidaxomicin for Treatment of Recurrent Clostridium difficile Infection.粪便微生物移植优于非达霉素治疗复发性艰难梭菌感染。
Gastroenterology. 2019 Apr;156(5):1324-1332.e3. doi: 10.1053/j.gastro.2018.12.019. Epub 2019 Jan 2.
9
Systematic review with meta-analysis: the efficacy of faecal microbiota transplantation for the treatment of recurrent and refractory Clostridium difficile infection.系统评价与荟萃分析：粪便微生物群移植治疗复发性和难治性艰难梭菌感染的疗效
Aliment Pharmacol Ther. 2017 Sep;46(5):479-493. doi: 10.1111/apt.14201. Epub 2017 Jul 14.
10
Duodenal infusion of donor feces for recurrent Clostridium difficile.经十二指肠输注供体粪便治疗复发性艰难梭菌感染。
N Engl J Med. 2013 Jan 31;368(5):407-15. doi: 10.1056/NEJMoa1205037. Epub 2013 Jan 16.
Zotero 插件